Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment

Conditions:   Childhood Central Nervous System Choriocarcinoma;   Childhood Central Nervous System Embryonal Tumor;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma;   Childhood Central Nervous System Mixed Germ Cell Tumor;   Childhood Central Nervous System Teratoma;   Childhood Central Nervous System Yolk Sac Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Central Nervous System Embryonal Tumor;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Visual Pathway Glioma;   Unspecified Childhood Solid Tumor, Protocol SpecificInterventions:   Drug: pazopanib hydrochloride;   Other: pharmacological studySponsors:   National Cancer Institute (NCI);   National Cancer Institute (NCI)Active, not recruiting - verified December 2012
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials